| Detected | Trial | Change |
|---|---|---|
| 2026-06-10 | NCT06700343 Comparison Between ABP 692 and Ocrevus® (Ocrelizumab) |
overall status: "Recruiting" → "Active Not Recruiting" |
| 2026-06-10 | NCT06700343 Comparison Between ABP 692 and Ocrevus® (Ocrelizumab) |
Enrollment reduced: 444 -> 152 participants |
| 2026-05-28 | NCT06780150 A Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain… |
Trial sites expanded: 84 -> 90 locations |
| 2026-05-23 | NCT07282574 A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of… |
Trial sites expanded: 47 -> 73 locations |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-05-19 | NCT07597668 A Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of… | Phase 1 | Active, Not Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT05285891 | Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis | Multiple Sclerosis | Recruiting |
| NCT07389590 | Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis | Multiple Sclerosis | Recruiting |
| NCT07483450 | A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of… | Relapsing Multiple Sclerosis | Recruiting |
| NCT04466150 | Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset | Relapsing Multiple Sclerosis | Active, Not Recruiting |
| NCT06495593 | Effects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting | Enrolling by Invitation |
| NCT04387734 | Effects of Ocrevus in Relapsing Multiple Sclerosis | Relapsing Multiple Sclerosis | Active, Not Recruiting |
| NCT05296161 | B Cell Tailored Ocrelizumab Versus Standard Ocrelizumab in Relapsing Remitting Multiple… | Multiple Sclerosis, Relapsing-Remitting | Active, Not Recruiting |
| Phase 3 | |||
| NCT07321093 | A Study of the Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting… | Relapsing-remitting Multiple Sclerosis (RRMS) | Recruiting |
| NCT06675955 | An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and… | Multiple Sclerosis | Recruiting |
| NCT06846281 | Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants… | Relapsing Multiple Sclerosis | Recruiting |
| NCT05123703 | A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in… | Relapsing-Remitting Multiple Sclerosis | Active, Not Recruiting |
| NCT04035005 | A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary… | Multiple Sclerosis, Primary Progressive | Active, Not Recruiting |
| NCT04544449 | A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in… | Multiple Sclerosis, Primary Progressive | Active, Not Recruiting |
| NCT04548999 | A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of… | Multiple Sclerosis | Active, Not Recruiting |
| NCT03523858 | A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple… | Progressive Multiple Sclerosis (PMS) | Active, Not Recruiting |
| NCT04544436 | A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of… | Multiple Sclerosis | Active, Not Recruiting |
| NCT05269004 | A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients… | Multiple Sclerosis | Active, Not Recruiting |
| NCT06700343 | Comparison Between ABP 692 and Ocrevus® (Ocrelizumab) | Relapsing-remitting Multiple Sclerosis (RRMS) | Active, Not Recruiting |
| NCT04688788 | Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis | Relapsing Remitting Multiple Sclerosis | Active, Not Recruiting |
| Phase 2 | |||
| NCT07282574 | A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of… | Progressive Multiple Sclerosis | Recruiting |
| Phase 1 | |||
| NCT07597668 | A Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of… | Multiple Sclerosis | Active, Not Recruiting |
| Not specified | |||
| NCT07207148 | People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists | Multiple Sclerosis | Recruiting |
| NCT06780150 | A Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain… | Multiple Sclerosis | Recruiting |
| NCT05688436 | A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants… | Multiple Sclerosis | Active, Not Recruiting |